LFCR

CHASKA, Minn., April 22, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore") a fully integrated injectables contract development and manufacturing organization ("CDMO"), today announced that effective on April 20, 2026, Lifecore granted a restricted stock unit ("RSU") award with respect to 5,000 shares of its common stock under Lifecore's Equity Inducement Plan, as amended (the "Inducement Plan") to a newly hired employee of Lifecore. The RSU award was granted pursuant to the offer letter between Lifecore and the employee, and as a material inducement to the employee joining Lifecore. The RSU award was approved by Lifecore's compensation committee and was granted

4 - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Issuer)

CHASKA, Minn., April 08, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) ("Lifecore"), a fully integrated injectables contract development and manufacturing organization ("CDMO"), today announced that the company will participate at the 12th Annual American Biomanufacturing Summit. The conference will take place April 14 - 15, 2026, in San Francisco, CA. Details regarding Lifecore's participation are as follows: 12th Annual American Biomanufacturing SummitDetails: Lifecore team will be present to discuss process development and manufacturing services for injectables programs.Booth number: 41 Conference Dates: April 14 - 15, 2026Location: Hyatt Regency San Francisco Airp

CHASKA, Minn., March 26, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore") a fully integrated injectables contract development and manufacturing organization ("CDMO"), today announced that effective on March 25, 2026, Lifecore granted a restricted stock unit ("RSU") award with respect to 18,500 shares of its common stock under Lifecore's Equity Inducement Plan, as amended (the "Inducement Plan") to a newly hired employee of Lifecore. The RSU award was granted pursuant to the offer letter between Lifecore and the employee, and as a material inducement to the employee joining Lifecore. The RSU award was approved by Lifecore's compensation committee and was grante

-- Site Transfer Agreement for the Manufacture of Commercially Marketed Product -- -- Second Agreement Supports the Expansion of Product Commercially Manufactured at Lifecore to a New Delivery System -- -- Fourth Commercial Site Transfer Agreement Win in Five Months -- -- Both Programs are Additive to Lifecore's High-Value, Late-Stage Pipeline and Expected to Contribute to 2028 Commercial Revenue -- CHASKA, Minn., March 26, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore"), a fully integrated injectables contract development and manufacturing organization ("CDMO"), today announced that it has signed two CDMO manufacturing service agreements with an existing

-- Agreement for the Commercial Manufacture of Established, Approved Aesthetic Product -- -- Third Commercial Site Transfer Agreement Win in Five Months -- -- Program Expected to Generate Commercial Revenue in 24 Months, Contributing to 2029 Revenue CAGR -- CHASKA, Minn., March 23, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore"), a fully integrated injectables contract development and manufacturing organization ("CDMO"), today announced that it has signed a CDMO manufacturing services agreement with a new aesthetics customer for an established, market-approved product. Under the terms of the agreement, Lifecore will perform technical transfer services inclu

Barrington Research upgraded Lifecore Biomedical from Mkt Perform to Outperform and set a new price target of $5.50

10-KT - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Filer)

8-K - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Filer)

-- Recorded Fourth Quarter Revenues of $35.7 Million and Transition Period Revenues of $75.5 Million -- -- Multiple New Programs Signed in Fourth Quarter 2025 Including Two Commercial Site Transfer Programs, for Total of Five New Programs in 2025 Transition Period -- -- Organizational Initiatives Drive Further Improvement in Margins -- Conference Call Today at 8:30am ET CHASKA, Minn., March 16, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore" or the "Company"), a fully integrated injectables contract development and manufacturing organization ("CDMO"), today announced strong results for the fourth quarter and transition period ended December 31, 2025

CHASKA, Minn., March 10, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) ("Lifecore"), a fully integrated injectables contract development and manufacturing organization ("CDMO"), today announced that the company will participate in the upcoming KeyBanc Capital Markets Healthcare Virtual Forum. Details regarding Lifecore's participation are as follows: 6th Annual KeyBanc Capital Markets Healthcare Virtual Forum Details: Mr. Josephs will be a featured speaker in a fireside chat and Lifecore management will participate in investor meetingsConference Dates: March 17 – 18, 2026Fireside Chat Time/Date: 9:00am – 9:35am Eastern Time on Tuesday, March 17, 2026, webcast availabl

CHASKA, Minn., March 09, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) ("Lifecore"), a fully integrated injectables contract development and manufacturing organization ("CDMO"), today announced that it will report financial results for the fourth quarter and transition period ended December 31, 2025, on Monday, March 16, 2026, before the market opens. At 8:30 a.m. Eastern Time that day, members of Lifecore's senior management team will host a webcast to discuss the results. To listen to the live webcast, or access the archived webcast, please visit the Investor Events & Presentations page of Lifecore's website at: https://ir.lifecore.com/events-presentations. Following

8-K - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Filer)

Indomo Developing Fast-Acting, At-Home Treatment for Inflammatory Acne Lesions to be Administered with the ClearPen™, its Proprietary Intradermal Self-Injection Device Lifecore to Manufacture Drug Batches in Preparation for Planned Clinical Trials CHASKA, Minn. and BOSTON, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore"), a fully integrated injectables contract development and manufacturing organization ("CDMO"), and Indomo, a clinical-stage company dedicated to expanding access to quality healthcare via innovative device-enabled therapeutics, today announced that the companies have entered into a new development services agreement through w

4 - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Issuer)

CHASKA, Minn., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) ("Lifecore"), a fully integrated injectables contract development and manufacturing organization ("CDMO"), today announced that the company will participate at DCAT Week 2026. The conference will take place March 23-26, 2026, in New York City. Details regarding Lifecore's participation are as follows: DCAT Week 2026Details: Lifecore team will host customers and prospective partners to discuss development and manufacturing solutions for existing and new injectable programs. Conference Dates: March 23-26, 2026Location: New York, NY If you are interested in meeting with Lifecore during DCAT week, plea

CHASKA, Minn., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore") a fully integrated contract development and manufacturing organization ("CDMO"), today announced that on January 14, 2026, the Lifecore compensation committee approved grants under Lifecore's Equity Inducement Plan, as amended (the "Inducement Plan") of restricted stock unit ("RSU") awards with respect to an aggregate 1,738 shares of its common stock and stock options for an aggregate 8,775 shares of common stock to two newly hired employees of Lifecore. The RSU award and stock options were granted on January 14, 2026, pursuant to the offer letters between Lifecore and each employee, and a

8-K - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Filer)

CHASKA, Minn., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) ("Lifecore"), a fully integrated contract development and manufacturing organization ("CDMO"), today announced that it has been notified by Nasdaq that the company's stock is expected to be added to the Nasdaq Biotech Index (NASDAQ:NBI) as part of the annual reconstitution of the 2025 Nasdaq indexes. Lifecore's inclusion in the Nasdaq Biotech Index will be effective prior to market open on Monday, December 22, 2025. The Nasdaq Biotechnology Index is designed to track the performance of a set of Nasdaq-listed securities that are classified as either biotechnology or pharmaceutical according to the Ind

Agreement Calls for Development Services and Tech Transfer in Preparation for Commercial Manufacturing of Injectable Pharmaceutical Product Partner's Program Size Positions it to Become a Top Five Commercial Customer for Lifecore CHASKA, Minn., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore"), a fully integrated contract development and manufacturing organization ("CDMO"), today announced that it has signed a CDMO master services agreement with a new large global pharmaceutical customer. Under the terms of the agreement, Lifecore will conduct development services and tech transfer for an injectable pharmaceutical product with the intent to transfer c

CHASKA, Minn., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) ("Lifecore"), a fully integrated contract development and manufacturing organization ("CDMO"), today announced that the company will participate at the 44th Annual J.P. Morgan Healthcare Conference. The conference will take place January 12-15, 2026, in San Francisco, California. Details regarding Lifecore's participation are as follows: 44th Annual J.P. Morgan Healthcare ConferenceDetails: Lifecore management, including Paul Josephs, chief executive officer, and Ryan Lake, chief financial officer, will participate in 1-on-1 meetings Conference Dates: January 12-15, 2026Location: San Francisco, Cali

8-K - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Filer)

CHASKA, Minn, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) ("Lifecore"), a fully integrated contract development and manufacturing organization ("CDMO"), today announced that the company will participate in two upcoming investor conferences. Details regarding Lifecore's participation are as follows: Jefferies 2025 Global Healthcare Conference – London Details: Paul Josephs, Lifecore's president and chief executive officer, will deliver a corporate presentation and Lifecore management will participate in investor meetingsConference Dates: November 17-20, 2025Presentation Time/Date: 9:30 – 9:55 a.m. Greenwich Mean Time (4:30 – 4:55 a.m. Eastern Time) on Tuesda

10-Q - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Filer)

8-K - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Filer)